Impact of a Ten-Year National Italian Networking on Cardiac Complications in Patients with Thalassemia Major
| Autor: | Anna Maria Petrungaro, Ada Riva, Rosamaria Rosso, Maria Grazia Roberti, Aurelio Maggio, Maurizio Caniglia, Roberto Mattei, Alessia Pepe, Antonella Meloni, Pier Paolo Bitti, Annamaria Carrà, Vincenzo Positano, Riccardo Righi, Laura Pistoia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Blood. 132:1055-1055 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2018-99-112546 |
| Popis: | Introduction. The MIOT (Myocardial Iron Overload in Thalassemia) Network was a national Italian network constituted by thalassemia and magnetic resonance imaging (MRI) centers built in 2006. The main aim was to assure available, accessible homogeneous and standardized T2* MRI cardiac and liver iron overload assessments for a significant number of patients with emoglobinopathies. Moreover, the creation of a solid clinical-instrumental web based database allowed data exchange between centers and constituted a means of monitoring health care processes and outcomes. We describe the impact of this ten-year Network on cardiac complications in patients with thalassemia major (TM). Methods. Among the 2497 emoglobinopathies patients consecutively enrolled in the MIOT Network we considered the 1401 TM patients who performed an end-of-study MRI. Per protocol the MRI follow up was scheduled every 18±3 months. Myocardial iron overload (MIO) was quantified by the multislice multiecho T2* technique. Biventricular function was quantified by cine images. Results. At the last MRI significantly higher global heart T2* values (35.5±10.7 ms vs 29.2±12.0 ms; P In patients with significant baseline MIO (global heart T2* Based on MRI results the 75% of the patients changed the chelation therapy. At the last MRI the percentage of patients with an excellent/good compliance was significantly higher (94.7% vs 92.7%%; P=0.034). The 13.1% of the patients had a cardiac complication (heart failure, arrhythmias, pulmonary hypertension, myocardial infarction, angina, myo/pericarditis, and peripheral vascular disease) before the enrolment in the project. During the study, the frequency of cardiac complications was 7.9 %, significantly lower (P Conclusion. Over a period of 10 years, the continuous monitoring of cardiac iron levels and a tailored chelation therapy allowed a reduction of MIO in the 70% of patients and a consequent improvement of cardiac function and reduction of heart failure. So, a national networking as the MIOT project was effective in improving the care and reducing cardiac outcomes of TM patients. Figure 1 Figure 1. Disclosures Pepe: Chiesi Farmaceutici S.p.A., ApoPharma Inc., and Bayer: Other: No profit support. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|